Preventing AIDS with LDN in Mali, Africa

Click here to visit Preventing AIDS with LDN in Mali, Africa website

The AIDS situation in Africa has reached a pandemic level. More than 26 million people are HIV-positive, over 6 million have active AIDS and 11 million have already died as a result of the devastating illness.

Of those newly infected, over 60% are women, many with children also infected. In sub-Saharan Africa one-half of the 14 million orphans are estimated to be HIV+ and 50% of untreated newborn HIV+ babies will die before the age of two. HAART drugs are available to less than 25% of those who need them (only 6% of children) due to cost and lack of medical personnel. Not only are these drugs costly and complex to administer, they are often too toxic for children who are even more difficult to manage medically.

Our recent discovery of the effectiveness of NALTREXONE in ultra low doses (LDN) to strengthen the immunity of autistic children started us on this pathway of wanting to help with HIV/AIDS in Africa. If proven effective in our controlled, clinical study in Mali, this easily managed, inexpensive non-toxic drug can keep HIV-positive persons from progressing to AIDS.

The implications are enormous.